



Running Contract Details	
Equipment Name	Interferon Gamma Release Assay Kit
Running Contract Valid Till	31-12-2026
Tender Ref No	KMSCL/EP/T544/1541/2024
Tendered Quantity	200000
Supplier Name	M/s EOS HEALTHCARE
GST No	32BGTPS6978M1Z6
Installation & Delivery Period	8 Week(s)
Up-time / PM vist	95% & 0 Visits per year
Warranty period	0 Years

Supplier`s Details		
Address	Contact Details	
67/12367A STANLEY BUILDING ST. ALBERT'S HIGH SCHOOL LANE KOCHI-682035	Contact Person	SANGEETH STANLEY
	Phone	
	Mobile No	9447701415
	Email	eos.kochi@ gmail.com

Item-wise Price Details				
#	Item Details	Unit Rate (Incl.all taxes & charges)	Service Charges (Through KMSCL)	Grand Total
1	Interferon Gamma Release Assay Kit <i>Model & Make : N/A</i>	1260 Incl.GST :5%	99.12	1359.12
		1260	99.12	1359.12

Other terms & conditions

1. The supplier shall execute an agreement with the purchaser as per tender conditions (agreement format is given in the tender document).
2. The supplier shall submit performance security amounting to 5.00% of the value of the supply order.
3. The labour & comprehensive charges of equipment after the completion of warranty period is finalized by KMSCL as mentioned above.
4. Since discount rate is not applicable for equipment under Running Contract of KMSCL, purchase/supply order can be issued directly to supplier at the given rate with tax & other charges (exclusive of KMSCL service charges).

5. If purchase/supply order is issued directly to the supplier, KMSCL service charge need not be paid. But the copy of the said order may be forwarded to KMSCL for information.

Technical Specification

Equipment :Interferon Gamma Release Assay Kit

Equipment: Interferon Gamma Release Assay kit

1. ELISA based Interferon Gamma Release Assay (IGRA) must use Blood collection tube precoated with a peptide cocktail on inner surface simulating ESAT-6 and CFP-10 proteins to stimulate cells in heparinized whole blood with no tedious lymphocyte isolation, subjective cell counting, diluting or culturing.
2. Ability to detect latent tuberculosis infection (LTBI), especially among recently exposed contacts, immunocompromised hosts, and young children
3. ELISA based Interferon Gamma Release Assay should be Drug Controller General of India approved (Copy should be submitted along with Technical Offer form) with local registered office of the manufacturer to provide technical and post - sales support
4. Detection of InterFeron- γ (IFN- γ) by enzyme-linked immunosorbent assay (ELISA) to identify in vitro responses to those peptide antigens that are associated with Mycobacterium tuberculosis infection
5. ELISA based IGRA with a negative control blood collection tube that adjusts for background levels of IFN- γ (TB1) & (TB2) that assess the Interferon-Gamma (IFN- γ) response by CD4 and CD8 respectively to TB-specific antigens coated inside tube and tube that serves as a positive control (Mitogen), which can be useful to indicate the immune status of the person being tested and that correct blood handling has occurred
6. The reconstituted kit standard may be kept for up to 3 months if stored at 2°C to 8°C. The unused Conjugate 100x Concentrate stored at 2°C to 8°C must be used within 3 months
7. ELISA based IGRA should enable blood Collection in Nil tube, TBI tube, TB2 tube, and a Mitogen tube as part of testing kit. Alternatively, blood may be collected from the field in a single generic blood collection tube that contains lithium heparin as the anticoagulant, and then transferred to TB specific Antigen pre-coated blood collection tubes (Nil/ TB1, TB2 and Mitogen tube).
8. Interferon Gamma Release Assay test approved or endorsed by World Health Organisation, US FDA approved and CE / IVD for Latent TB Infection testing and have necessary permission for distribution in India.
9. Whole-blood based enzyme-linked immunosorbent assays (ELISAs) measuring the amount of IFN- γ produced in response to two M. tuberculosis antigens
10. Prior BCG (BacilleCalmette-Guérin) vaccination should not cause a false-positive test result. IGRA should not have a cross reactivity with Bacille-CalmetteGuérin (BCG) vaccination and should not be affected by the pre administered vaccine
11. Test with 95% sensitivity and 98% specificity and accurately identify TB-infected patients
12. IGRA with Published scientific evidence that underlines the future potential of CD8+ T cells in distinguishing active from latent TB, discerning recent vs. old infections, detecting TB in certain risk populations (such as HIV co-infection and young children) should be supported by documented evidence.
13. ELISA based IGRA test manufacturer with demonstrated experience of providing the kits/ consumables, technical training and post-sales support with instrumentation to Government of India or its affiliated institutes like National TB Elimination Program/ State TB Programs/ICMR for projects and studies.
14. IGRA with an option to collect and store blood sample in single Lithium Heparin tube or Sodium Heparin tube for transportation purpose from field to testing site for up to 48 hours at 2-8 °C, subsequently transferred in lab to TB specific Antigen pre-coated blood collection tubes (Nil/ TB1, TB2 and Mitogen tube) for further processing.
15. ELISA based IGRA Kit manufacturer to provide software for data analysis and interpretation of result
16. Reference Purchase orders from National TB Elimination Program/ State TB Programs/ICMR and other government institute orders
17. Manufacturer of ELISA based test kits shall have certification of international standards/ GMP Certification
18. IGRA that is easily automatable and scalable for high-through put testing laboratories/ Hospitals & national mass Screening projects requiring only 37 °C incubator, centrifuge and ELISA reader (optional ELISA washer), pipettes and lab consumables
19. The test should also have a second TB antigen tube that contains an additional act of peptides to elicit responses from CD8+ T lymphocytes. The assay should include a positive mitogen control and a negative control
20. The limit of detection should be atleast 0.05 IU / ml
21. Analysis software should be provided by the manufacturer for use as required. The Software may be used to analyze raw data and calculate results
22. The Analysis software provided by the manufacturer must perform a quality control assessment of the assay, generate a

standard curve, and provide a test result for each subject.

23. The Analysis Software provided by the manufacturer must calculate and report the quality control parameters like mean OD value for Standard, % CV for Standard replicate and correlation coefficient (r) from the mean absorbance values of Standards.